ONCOGENEX ANNOUNCES PLANS FOR THE INITIATION OF THE "Borealis-2" CLINICAL TRIAL EVALUATING OGX-427 IN COMBINATION WITH SECOND-LINE CHEMOTHERAPY FOR BLADDER CANCER

OncoGenex focuses on diverse molecular entities that target mechanisms of resistance and that have the potential to re-define treatment paradigms in a variety of cancers.